Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2094193rdf:typepubmed:Citationlld:pubmed
pubmed-article:2094193lifeskim:mentionsumls-concept:C0026769lld:lifeskim
pubmed-article:2094193lifeskim:mentionsumls-concept:C0024141lld:lifeskim
pubmed-article:2094193lifeskim:mentionsumls-concept:C0007806lld:lifeskim
pubmed-article:2094193lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:2094193lifeskim:mentionsumls-concept:C0162595lld:lifeskim
pubmed-article:2094193lifeskim:mentionsumls-concept:C0039082lld:lifeskim
pubmed-article:2094193pubmed:issue4lld:pubmed
pubmed-article:2094193pubmed:dateCreated1991-6-27lld:pubmed
pubmed-article:2094193pubmed:abstractTextImmunoglobulins isotypes (IgG and IgM) for myelin basic protein (MBP), cerebrosides (CER), gangliosides (GANG) and cardiolipin (CARD) were detected in the cerebrospinal fluid (CSF) from 33 patients with multiple sclerosis (MS), 18 with Guillain-Barré syndrome (GBS) and 30 with systemic lupus erythematosus (SLE). In MS patients occurred positive and significant levels of IgG-MBP in 51.5% (p less than 0.05) and IgM-MBP in only 18.2%, IgG-CARD in 46.2%, as long as CER and GANG were detected in almost 20%. From serum samples of MS patients 20.6% presented IgG-MBP, while 53% showed positive levels for IgM-MBP. The CSF analysis of patients with GBS showed that 56.3% revealed IgG-MBP (p less than 0.05), 53% for IgM-MBP, 38.5% for IgG-CER and 23% for IgM-CER, while 50% of patients had IgG-CARD, as long as 31% also had IgG-GANG. The serum evaluation from 14 patients showed that 18.8% had positive concentrations of IgG-MBP and 56.3% presented IgM-MBP (p less than 0.05). Except for 50% of patients with SLE who presented positive CSF levels of IgG-CARD, only 24.1% had positive levels of IgG-MBP. We believe that the presence of antiphospholipid antibodies in CSF of the above mentioned diseases occurred as immune epiphenomena, but their appearance would permit the maintenance of and perpetuate the immune event.lld:pubmed
pubmed-article:2094193pubmed:languageenglld:pubmed
pubmed-article:2094193pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2094193pubmed:citationSubsetIMlld:pubmed
pubmed-article:2094193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2094193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2094193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2094193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2094193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2094193pubmed:statusMEDLINElld:pubmed
pubmed-article:2094193pubmed:monthDeclld:pubmed
pubmed-article:2094193pubmed:issn0004-282Xlld:pubmed
pubmed-article:2094193pubmed:authorpubmed-author:ScaffMMlld:pubmed
pubmed-article:2094193pubmed:authorpubmed-author:MarchioriP...lld:pubmed
pubmed-article:2094193pubmed:authorpubmed-author:CallegariBBlld:pubmed
pubmed-article:2094193pubmed:authorpubmed-author:De...lld:pubmed
pubmed-article:2094193pubmed:authorpubmed-author:QuevedoM EMElld:pubmed
pubmed-article:2094193pubmed:authorpubmed-author:HirataM TMTlld:pubmed
pubmed-article:2094193pubmed:authorpubmed-author:Dos ReisMMlld:pubmed
pubmed-article:2094193pubmed:issnTypePrintlld:pubmed
pubmed-article:2094193pubmed:volume48lld:pubmed
pubmed-article:2094193pubmed:ownerNLMlld:pubmed
pubmed-article:2094193pubmed:authorsCompleteYlld:pubmed
pubmed-article:2094193pubmed:pagination465-8lld:pubmed
pubmed-article:2094193pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:2094193pubmed:meshHeadingpubmed-meshheading:2094193-...lld:pubmed
pubmed-article:2094193pubmed:meshHeadingpubmed-meshheading:2094193-...lld:pubmed
pubmed-article:2094193pubmed:meshHeadingpubmed-meshheading:2094193-...lld:pubmed
pubmed-article:2094193pubmed:meshHeadingpubmed-meshheading:2094193-...lld:pubmed
pubmed-article:2094193pubmed:meshHeadingpubmed-meshheading:2094193-...lld:pubmed
pubmed-article:2094193pubmed:meshHeadingpubmed-meshheading:2094193-...lld:pubmed
pubmed-article:2094193pubmed:meshHeadingpubmed-meshheading:2094193-...lld:pubmed
pubmed-article:2094193pubmed:meshHeadingpubmed-meshheading:2094193-...lld:pubmed
pubmed-article:2094193pubmed:meshHeadingpubmed-meshheading:2094193-...lld:pubmed
pubmed-article:2094193pubmed:meshHeadingpubmed-meshheading:2094193-...lld:pubmed
pubmed-article:2094193pubmed:year1990lld:pubmed
pubmed-article:2094193pubmed:articleTitleCerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barré syndrome and systemic lupus erythematosus.lld:pubmed
pubmed-article:2094193pubmed:affiliationDivision of Neurology, São Paulo University Medical School, Brasil.lld:pubmed
pubmed-article:2094193pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2094193pubmed:publicationTypeComparative Studylld:pubmed